Skip to main content
Erschienen in: Annals of Hematology 12/2019

01.11.2019 | Letter to the Editor

Response to interferon treatment in essential thrombocythemia with inv(3)(q21q26)

verfasst von: Radhika Gangaraju, Andrew J. Carroll, Josef T. Prchal

Erschienen in: Annals of Hematology | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …
Literatur
1.
Zurück zum Zitat Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRef Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRef
2.
Zurück zum Zitat Yamazaki H, Suzuki M, Otsuki A et al (2014) A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell 25:415–427CrossRef Yamazaki H, Suzuki M, Otsuki A et al (2014) A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell 25:415–427CrossRef
3.
Zurück zum Zitat Pintado T, Ferro MT, San Roman C et al (1985) Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer 55:535–541CrossRef Pintado T, Ferro MT, San Roman C et al (1985) Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer 55:535–541CrossRef
4.
Zurück zum Zitat Reiter E, Greinix H, Rabitsch W, Keil F, Schwarzinger I, Jaeger U, Lechner K, Worel N, Streubel B, Fonatsch C, Mitterbauer G, Kalhs P (2000) Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversion inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26). Ann Hematol 79:374–377CrossRef Reiter E, Greinix H, Rabitsch W, Keil F, Schwarzinger I, Jaeger U, Lechner K, Worel N, Streubel B, Fonatsch C, Mitterbauer G, Kalhs P (2000) Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversion inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26). Ann Hematol 79:374–377CrossRef
5.
Zurück zum Zitat Villalon C, Talavera M, Sordo MT et al (2008) Association of inv(3)(q21q26) with essential thrombocythemia in transformation. Cancer Genet Cytogenet 184:122–123CrossRef Villalon C, Talavera M, Sordo MT et al (2008) Association of inv(3)(q21q26) with essential thrombocythemia in transformation. Cancer Genet Cytogenet 184:122–123CrossRef
Metadaten
Titel
Response to interferon treatment in essential thrombocythemia with inv(3)(q21q26)
verfasst von
Radhika Gangaraju
Andrew J. Carroll
Josef T. Prchal
Publikationsdatum
01.11.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 12/2019
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-019-03805-9

Weitere Artikel der Ausgabe 12/2019

Annals of Hematology 12/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.